{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:12:58Z","timestamp":1793643178689,"version":"4.5.1"},"reference-count":67,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Inflammatory bowel diseases (IBDs) are chronic and disabling conditions that, uncontrolled, lead to irreversible bowel damage and associated comorbidities. Despite the new era of biological therapies, IBDs remain not curative. The treatment purpose is to induce endoscopic remission, reduce the progression of the disease and improve the quality of life. Optimal and early treatment could enable the prevention of their complications. Small molecules, administrated as oral agents, have the capacity of overcoming the limitations of biologic agents (i.e., parenteral administration, rapidity of action and primary and secondary non-responsiveness). Of special interest are results from the use of oral sphingosine 1-phosphate (S1P) receptor modulators (ozanimod, etrasimod, fingolimod and laquinimod), based on S1P activities to target lymphocyte recirculation in the mucosa, acting as immunosuppressive agents. Most S1P modulators are reported to be safe and effective in the treatment of both UC and CD. High and satisfactory rates of clinical remission as well as endoscopic improvement and remission can be achieved with these molecules. Safety alarms remain rather low, although the S1P binding to two of its G protein-coupled receptors, 2 and 3 (S1PR2 and S1PR3), may be associated with cardiovascular risks. Cost-effectiveness studies and head-to-head trials are needed to better define their place in therapy. This review summarizes these emerging data published by PubMed and EMBASE databases and from ongoing clinical trials on the safety and efficacy of selectivity of S1P modulators in the treatment of IBD.<\/jats:p>","DOI":"10.3390\/biomedicines10071735","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T05:37:53Z","timestamp":1658209073000},"page":"1735","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8543-4355","authenticated-orcid":false,"given":"Arianna","family":"Dal Buono","sequence":"first","affiliation":[{"name":"IBD Center, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089  Rozzano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gabbiadini","sequence":"additional","affiliation":[{"name":"IBD Center, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089  Rozzano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9702-4508","authenticated-orcid":false,"given":"Ludovico","family":"Alfarone","sequence":"additional","affiliation":[{"name":"IBD Center, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089  Rozzano, Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-6778","authenticated-orcid":false,"given":"Virginia","family":"Solitano","sequence":"additional","affiliation":[{"name":"IBD Center, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089  Rozzano, Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Repici","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Milan, Italy"},{"name":"Endoscopy Unit, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Vetrano","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Milan, Italy"},{"name":"IBD Center, Laboratory of Immunology in Gastroenterology, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1493-1768","authenticated-orcid":false,"given":"Antonino","family":"Spinelli","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Milan, Italy"},{"name":"Colon and Rectal Surgery Division, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[{"name":"IBD Center, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089  Rozzano, Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn\u2019s disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: Medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in crohn\u2019s disease: Medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/apt.14030","article-title":"Systematic review with meta-analysis: Comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn\u2019s disease and ulcerative colitis controlled trials","volume":"45","author":"Cholapranee","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.14309\/ajg.0000000000000111","article-title":"Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"114","author":"Battat","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/apt.15005","article-title":"Systematic review with network meta-analysis: The impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life","volume":"48","author":"Paschos","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/00365521.2020.1722738","article-title":"Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance infliximab treatment in inflammatory bowel disease","volume":"55","author":"Hossain","year":"2020","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/apt.12749","article-title":"Systematic review with network meta-analysis: The efficacy of anti-TNF agents for the treatment of Crohn\u2019s disease","volume":"39","author":"Stidham","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","article-title":"Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis","volume":"12","author":"Singh","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gisbert, J.P., and Chaparro, M. (2021). Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?. J. Clin. Med., 10.","DOI":"10.3390\/jcm10225318"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/ibd\/izaa081","article-title":"The cost of inflammatory bowel disease: An initiative from the crohn\u2019s & colitis foundation","volume":"26","author":"Park","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"17562848211006668","DOI":"10.1177\/17562848211006669","article-title":"Novel trends with biologics in inflammatory bowel disease: Sequential and combined approaches","volume":"14","author":"Privitera","year":"2021","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s13046-020-01740-6","article-title":"Unveiling role of sphingosine-1-phosphate receptor 2 as a brake of epithelial stem cell proliferation and a tumor suppressor in colorectal cancer","volume":"39","author":"Petti","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","volume":"16","author":"Christopher","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41575-021-00574-7","article-title":"Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease","volume":"19","author":"Verstockt","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_18","unstructured":"(2022, June 07). Mayzent [Prescribing Information]. Available online: https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/mayzent.pdf."},{"key":"ref_19","unstructured":"(2022, June 07). Gilenya [Prescribing Information]. Available online: https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/gilenya.pdf."},{"key":"ref_20","unstructured":"(2022, June 07). Zeposia [Prescribing Information], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209899s000lbl.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrm1103","article-title":"Sphingosine-1-phosphate: An enigmatic signalling lipid","volume":"4","author":"Spiegel","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev-immunol-020711-075011","article-title":"Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs","volume":"30","author":"Cyster","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1126\/science.1113640","article-title":"Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients","volume":"309","author":"Schwab","year":"2005","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.4049\/jimmunol.0903358","article-title":"Redistribution of sphingosine 1-phosphate by sphingosine kinase 2 contributes to lymphopenia","volume":"184","author":"Sensken","year":"2010","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.tips.2013.05.002","article-title":"The structure and function of the S1P1 receptor","volume":"34","author":"Dev","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1084\/jem.20041509","article-title":"Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit","volume":"201","author":"Lo","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.4049\/jimmunol.175.5.2960","article-title":"Sphingosine-1-phosphate mediates migration of mature dendritic cells","volume":"175","author":"Czeloth","year":"2005","journal-title":"J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s13311-017-0565-4","article-title":"Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis","volume":"14","author":"Chaudhry","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00054725-200405000-00002","article-title":"Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis","volume":"10","author":"Mizushima","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.4049\/jimmunol.178.4.2458","article-title":"FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells","volume":"178","author":"Daniel","year":"2007","journal-title":"J. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/17474124.2020.1709446","article-title":"Is there a role for therapeutic sphingolipids in inflammatory bowel disease?","volume":"14","author":"Parigi","year":"2020","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/2042098613481023","article-title":"Fingolimod and cardiac risk: Latest findings and clinical implications","volume":"4","author":"Vargas","year":"2013","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): A multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): A multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/17474124.2020.1785868","article-title":"PK, PD, and interactions: The new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD","volume":"14","author":"Gilardi","year":"2020","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sndborn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Danese, S., Colombel, J.F., Ponich, T., Jovanovic, I., Bossuyt, P., Longman, R., Alekseeva, O., Petersen, A., Chitkara, D., and Marta, C. (2022, January 16\u201319). Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis. Proceedings of the ECCO Congress 2022\u2014DOP44, Virtual.","DOI":"10.1093\/ecco-jcc\/jjab232.083"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","article-title":"Ozanimod induction therapy for patients with moderate to severe Crohn\u2019s disease: A single-arm, phase 2, prospective observer-blinded endpoint study","volume":"5","author":"Feagan","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","article-title":"Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results from the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study","volume":"15","author":"Sandborn","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S-969","DOI":"10.1016\/S0016-5085(22)62296-0","article-title":"Long-term use of ozanimod in patients with moderately to severely active ulcerative colitis\u2014DDW ePoster\u2014Tu1458","volume":"162","author":"Wolf","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Armuzzi, A., Cross, R.K., Lichtenstein, G., Danese, S., Vermeire, S., Zhou, W., Sands, B.E., Dignass, A., and Irving, P. (2022, January 16\u201319). Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosis. Proceedings of the ECCO Congress 2022\u2014DOP45, Virtual.","DOI":"10.1093\/ecco-jcc\/jjab232.084"},{"key":"ref_47","unstructured":"Cohen, N.A., Choi, D., Choden, T., Cleveland, N.K., Cohen, R.D., and Rubin, D.T. (2022). Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data from a Large Tertiary Center. Clin. Gastroenterol. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"i415","DOI":"10.1093\/ecco-jcc\/jjab232.558","article-title":"Early mucosal healing at week 10 with ozanimod predicts clinical outcomes at week 52: Post hoc analysis of the phase 3 True North clinical trial [ECCO abstract P431]","volume":"16","author":"Reinisch","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_49","unstructured":"Schreiber, S., Morgan, M., and Christopher, L. (2016, January 8\u201310). Etrasimod [APD334], a Potent, Selective, Oral S1P Receptor Modulator with Preclinical Autoimmune Disease-Modifying Activity Exhibits Favorable PK\/PD Properties in Healthy Volunteers. Proceedings of the Advances in Inflammatory Bowel Diseases (AIBD), Orlando, FL, USA."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Peyrin-Biroulet, L., Adams, J., Turner, S., Trokan, L., and Panes, J. (2018, January 14\u201317). Safety and immune modulatory properties of etrasimod [APD334], a next-generation oral, selective sphingosine 1-phosphate receptor [S1PR] modulator, in healthy volunteers. Proceedings of the ECCO Congress, Vienna, Austria.","DOI":"10.1093\/ecco-jcc\/jjx180.700"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study","volume":"15","author":"Vermeire","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S-1395","DOI":"10.1016\/S0016-5085(22)64063-0","article-title":"Etrasimod 2mg once daily as treatment for moderately to severely active ulcerative colitis: Results from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials\u2014Digestive Disease Week (DDW) 2022\u2014Abstract 968a","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40265-021-01528-8","article-title":"Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis","volume":"81","year":"2021","journal-title":"Drugs"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/bcp.13203","article-title":"Cardiac effects of amiselimod compared with fingolimod and placebo: Results of a randomised, parallel-group, phase I study in healthy subjects","volume":"83","author":"Harada","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/bph.13641","article-title":"Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk","volume":"174","author":"Sugahara","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Shimano, K., Maeda, Y., Kataoka, H., Murase, M., Mochizuki, S., Utsumi, H., Oshita, K., and Sugahara, K. (2019). Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0226154"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/ecco-jcc\/jjab232.023","article-title":"A Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn\u2019s Disease","volume":"16","author":"Danese","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_60","unstructured":"(2022, June 07). Bausch Health Picks Up IBD Drug Amiselimod Rejected by Biogen. Available online: https:\/\/www.thepharmaletter.com\/article\/bausch-health-picks-up-ibd-drug-amiselimod-rejected-by-biogen."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Sigmund, B., Axelrad, J., Pondel, M., Osterman, M.T., Ahmad, H.A., Memaj, A., Regueiro, M., Armuzzi, A., and Afzali, A. (2022, January 16\u201319). Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North\u2014ECCO 2022\u2014DOP43. Proceedings of the ECCO Congress, Virtual.","DOI":"10.1093\/ecco-jcc\/jjab232.082"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.devcel.2012.07.015","article-title":"Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development","volume":"23","author":"Jung","year":"2012","journal-title":"Dev. Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0092-8674(00)81661-X","article-title":"Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate","volume":"99","author":"Lee","year":"1999","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1007\/s10620-010-1421-0","article-title":"Sphingosine-1-phosphate regulates the expression of adherens junction protein E-cadherin and enhances intestinal epithelial cell barrier function","volume":"56","author":"Greenspon","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"102832","DOI":"10.1016\/j.autrev.2021.102832","article-title":"Combination therapy in inflammatory bowel disease\u2014From traditional immunosuppressors towards the new paradigm of dual targeted therapy","volume":"20","author":"Privitera","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Sands, B.E., Dignass, A., Irving, P., Chiorean, M., Long, M., Eren, D., Ahmad, H.A., Osterman, M.T., Petersen, A., and Elegbe, A. (2022, January 16\u201319). P316 Ozanimod is an efficacious oral therapy after 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: Post hoc analysis from True North\u2014ECCO Congress 2022\u2014P316. Proceedings of the ECCO Congress, Virtual.","DOI":"10.1093\/ecco-jcc\/jjab232.443"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"S-602","DOI":"10.1016\/S0016-5085(22)61422-7","article-title":"Comparative efficacy and safety of ozanimod and ustekinumab in patients with moderately to severely active ulcerative colitis\u2014DDW ePoster\u2014Su1500","volume":"162","author":"Dubinsky","year":"2022","journal-title":"Gastroenterology"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1735\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:53:29Z","timestamp":1760140409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":67,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["biomedicines10071735"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10071735","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]}}}